Printer Friendly

When antipsychotic drugs can be lethal.

When Antipsychotic Drugs Can Be Lethal

Neuroleptic drugs, also known as antipsychotic agents, are among the most commonly prescribed medications in the United States, used by up to 3 million people annually. Although in some cases neuroleptics lead to severe movement disorders and other side effects (SN: 7/20/85, p.45), psychiatrists have found that the drugs are often effective at moderating psychotic symptoms.

Yet, according to a report in the October AMERICAN JOURNAL OF PSYCHIATRY, a dangerous but little-known complication of antipsychotic drug use appears to be more common than previously thought. It often goes unrecognized in its early stages, add psychiatrist Harrison G. Pope Jr. and his colleagues of McLean Hospital in Belmont, Mass.

The complication is referred to as neuroleptic malignant syndrome, or NMS. Its cardinal signs are a fever, severe muscle rigidity, elevated blood pressure, elevated heart rate and clouded consciousness. The last feature can include delirium, stupor, mutism or coma. In some cases, a patient takes only a few hours to go from symptoms without serious illness to an inability to swallow, coma, kidney failure or brain damage. It is estimated that about 20 percent of the time, NMS is fatal. Death can result from respiratory, cardiovascular or kidney failure.

The researchers who first described the syndrome in 1968 estimated that it occurs among 0.5 to 1 percent of those taking neuroleptics, which are, among other things, powerful tranquilizers. Case reports of NMS have been published since then, but clinicians have considered the condition to be rare.

Pope and his co-workers, however, found seven definite or probable cases of NMS among an estimated 483 patients who received several types of neuroleptics at McLean Hospital over a recent one-year period. Another patient admitted during the study did not receive antipsychotic drugs because she had twice developed NMS during a previous admission. This prevalence rate of 1.4 percent is a conservative estimate, say the researchers; mild cases may have been missed, and some patients develop NMS years after going on the medication.

"In an extrapolation of our results,' note the psychiatrists, "even a conservative estimate would place the annual prevalence of [NMS] in the United States in the thousands of cases, a significant number of which may have fatal consequences.'

The good news, they say, is that many patients displaying symptoms of NMS recover fully when neuroleptic treatment is stopped. In addition, the muscle relaxant dantrolene and several medications that increase the transmission of the neurochemical dopamine in the brain (believed to be impeded by neuroleptics) have recently been shown to ease NMS. Low-dose neuroleptic treatment can begin again for some successfully treated patients.

Another encouraging trend is noted by Chester Pearlman of the Boston Veterans Administration Medical Center in the October JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. He reviewed 320 reported cases of NMS since 1968 and found that "with wider recognition, mortality [from NMS] has decreased from about 22 percent of cases reported through 1980 to 4 percent of the last 50.'

But much is still unknown about the syndrome's underlying causes, frequency and possible treatments. Even with the McLean study, it is hard to draw a conclusion about the true prevalence of NMS, according to Shervert Frazier, director of the National Institute of Mental Health (NIMH). Diagnostic changes in only a few of the subjects would have significantly altered the final percentage, he points out.

NMS "has been more recognized in the past few years, but I don't think it's occurring more often than the originally estimated rate of about 1 percent,' Frazier told SCIENCE NEWS.

A problem with any piece of research on NMS, says psychiatrist Darrell Kirch of St. Elizabeths Hospital in Washington, D.C., is that the condition's early signs are still unclear. At first, a fever or muscle rigidity cannot be exclusively linked to neuroleptic use. Frazier says an NIMH research team is beginning to look for reliable early signs of NMS.

For the time being, says psychiatrist David E. Sternberg in an editorial accompanying the McLean report, regular monitoring of blood pressure and muscle tone may lead to early recognition of NMS. Furthermore, he says, the syndrome appears to be more common among those under 40 years of age, males and patients with psychiatric disorders that do not include schizophrenia. Sternberg, of Falkirk Hospital in Central Valley, N.Y., concurs with the researchers that the lifetime risk of NMS will probably prove to be higher than the 1.4 percent one-year rate uncovered at McLean Hospital.
COPYRIGHT 1986 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1986, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:neuroleptic malignant syndrome
Author:Bower, Bruce
Publication:Science News
Date:Oct 25, 1986
Previous Article:First cancer-protecting gene characterized.
Next Article:Muscular dystrophy gene cornered.

Related Articles
Neuroleptic backlash.
TD hazards among the retarded.
'Borderline' drugs: a limited role.
Schizophrenia: new hope from an old drug.
New Look at antipsychotic side effect.
New report offers antipsychotic guidelines.
Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly.
Lethal injection is inhumane, say researchers.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters